CRIS Current Research Information System

VIANELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.824
AS - Asia 4.959
EU - Europa 3.422
AF - Africa 287
SA - Sud America 276
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.780
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.717
SG - Singapore 1.410
CN - Cina 1.254
VN - Vietnam 1.244
GB - Regno Unito 754
IT - Italia 580
SE - Svezia 521
DE - Germania 456
HK - Hong Kong 308
IN - India 241
FR - Francia 219
BR - Brasile 189
RU - Federazione Russa 181
IE - Irlanda 154
NL - Olanda 110
FI - Finlandia 94
KR - Corea 93
JP - Giappone 85
CI - Costa d'Avorio 83
ZA - Sudafrica 72
TG - Togo 69
CA - Canada 67
UA - Ucraina 66
BD - Bangladesh 60
EE - Estonia 56
BG - Bulgaria 42
JO - Giordania 40
BE - Belgio 39
PH - Filippine 38
CH - Svizzera 37
AR - Argentina 28
TH - Thailandia 28
MX - Messico 24
AT - Austria 23
ID - Indonesia 23
PL - Polonia 23
NG - Nigeria 21
TW - Taiwan 21
TR - Turchia 19
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 15
SA - Arabia Saudita 14
CO - Colombia 13
IQ - Iraq 13
CZ - Repubblica Ceca 12
LT - Lituania 11
ES - Italia 10
AU - Australia 9
PY - Paraguay 9
SC - Seychelles 9
PE - Perù 8
GR - Grecia 7
CL - Cile 6
EG - Egitto 6
ET - Etiopia 6
MA - Marocco 6
RO - Romania 6
DZ - Algeria 5
LB - Libano 5
LV - Lettonia 5
MY - Malesia 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
AL - Albania 3
CR - Costa Rica 3
DK - Danimarca 3
IL - Israele 3
JM - Giamaica 3
MK - Macedonia 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CG - Congo 2
CY - Cipro 2
GT - Guatemala 2
HR - Croazia 2
KE - Kenya 2
NZ - Nuova Zelanda 2
OM - Oman 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BS - Bahamas 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PR - Porto Rico 1
Totale 14.772
Salva come PNG Salva come JPEG
Città #
Singapore 968
Ashburn 664
Southend 635
Fairfield 555
Chandler 464
San Jose 395
Hong Kong 294
Seattle 244
Ho Chi Minh City 240
Woodbridge 236
Hanoi 233
Houston 233
Cambridge 232
Wilmington 216
Dong Ket 205
Ann Arbor 186
Santa Clara 183
Beijing 175
Hefei 174
Princeton 161
Dublin 152
Boardman 113
Bologna 113
Los Angeles 105
Lauterbourg 88
Abidjan 83
Dallas 83
New York 79
Helsinki 74
Seoul 74
Lomé 69
Tokyo 69
Nanjing 66
Westminster 64
Council Bluffs 54
Milan 54
Padova 54
Bremen 51
Munich 49
Berlin 44
Buffalo 44
Hyderabad 44
Sofia 42
Amman 40
Jinan 40
Turin 40
Brussels 39
Shenyang 39
Frankfurt am Main 37
Saint Petersburg 35
Cornaredo 32
Haiphong 32
Jacksonville 32
Bern 31
Da Nang 30
Redmond 28
São Paulo 28
Redondo Beach 27
Guangzhou 26
San Diego 24
Shanghai 24
London 23
Toronto 22
Chicago 21
Changsha 20
Johannesburg 19
Abeokuta 18
Nanchang 18
Phoenix 18
Zhengzhou 18
Bengaluru 17
Orem 17
Rome 17
Amsterdam 16
Falls Church 16
Hangzhou 16
Hebei 16
Jakarta 16
Nuremberg 16
Warsaw 16
Montreal 15
Can Tho 14
Des Moines 14
Tianjin 14
Biên Hòa 13
San Francisco 13
Brooklyn 12
Florence 12
Menlo Park 12
Falkenstein 11
Lappeenranta 11
Medford 11
Olalla 11
Redwood City 11
Clifton 10
Dearborn 10
Fremont 10
Istanbul 10
Jiaxing 10
Norwalk 10
Totale 9.519
Salva come PNG Salva come JPEG
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 263
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 243
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 227
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 226
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 224
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 221
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 213
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 212
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 211
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 207
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 206
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 203
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 199
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 198
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 196
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 191
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 188
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 186
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 186
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 185
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 181
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 180
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 179
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 177
A risk prediction score for invasive mold disease in patients with hematological malignancies 168
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 168
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 167
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 166
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 163
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 159
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 158
Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies 157
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 155
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 153
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B 152
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 146
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 145
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 142
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 142
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 142
Dexamethasone plus rituximab yieldshigher sustained response rates than dexamethasone monotherapy in adultswith primary immune thrombocytopenia 141
Retrospective cohort analysis of liposomal amphotericin b nephrotoxicity in patients with hematological malignancies 141
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 140
Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. 140
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 140
Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. 139
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 139
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 136
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 136
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 134
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 133
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 132
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 131
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 129
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 129
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 129
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 129
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 127
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 126
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. 126
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 126
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 125
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 124
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 124
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 122
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 121
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 118
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 116
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 114
The CD47 pathway is deregulated in human immune thrombocytopenia 114
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 113
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. 111
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 110
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 106
null 98
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 97
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 97
null 96
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 95
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 95
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 93
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 88
null 86
Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important? 56
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 56
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 56
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 44
Prompt plasma-exchange treatment and coma reversibility in two patients with thrombotic thrombocytopenic purpura 39
Totale 14.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021400 0 0 0 0 0 0 0 0 0 0 0 400
2021/20221.577 78 43 91 187 127 71 38 103 53 183 334 269
2022/20231.856 174 270 102 249 122 162 47 125 323 79 125 78
2023/2024554 40 92 45 65 44 95 9 40 18 37 38 31
2024/20252.184 121 278 180 196 284 118 147 101 74 150 109 426
2025/20265.125 409 400 457 379 530 259 466 323 1.111 441 192 158
Totale 15.071